Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7580472 | 0.83 | MEN1 (0.45) | — | |
| SCHEMBL7600141 | 0.81 | — | — | |
| SCHEMBL6690514 | 0.79 | EGFR (0.30) | — | |
| SCHEMBL2485392 | 0.79 | EGFR (0.30) | — | |
| SCHEMBL7064301 | 0.79 | — | — | |
| SCHEMBL4556547 | 0.78 | — | — | |
| Hydrazine SCHEMBL7600144 | 0.76 | — | — | |
| SCHEMBL9000091 | 0.76 | EGFR (0.32) | — | |
| SCHEMBL9000100 | 0.75 | TP53 (0.32) | — | |
| SCHEMBL9000086 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES INC (US) | 2025-03-13 | — | — | US | claimed |
| EP-4177356-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2024-05-08 | — | — | EP | claimed |
| EP-3947375-B1 | IMIDAZOLONYLQUINOLINE COMPOUNDS AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2024-04-03 | — | — | EP | claimed |
| EP-4177356-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2023-05-10 | — | — | EP | claimed |
| US-20230137849-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | AZELEAD (FR) | 2023-05-04 | — | — | US | claimed |
| EP-3625368-B1 | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING | PML SCREENING LLC (US) | 2022-11-09 | — | — | EP | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022177302-A1 | PYRIMIDINE-FUSED RING COMPOUND WITH DNA-PK INHIBITION ACTIVITY AND USE THEREOF | 보령제약 주식회사 | 2022-08-25 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| EP-1804816-B1 | COMBINATION THERAPY COMPRISING CLORETAZINE(TM) | VION PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | claimed |
| US-7605137-B2 | Combination therapy comprising cloretazine | VION PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | claimed |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137698-A1 | CYCLIN-DEPENDENT KINASE 7 INHIBITORS | JOINT STOCK CO «BIOCAD» (RU) | 2026-05-21 | — | — | US | disclosed |
| CN-1191482-A | Antitumor 2-aminocarbonyl-1, 2-bis (methylsulfonyl) -1- (substituted) hydrazines | UNIV YALE (US) | 1998-08-26 | — | — | CN | disclosed |
| EP-0841912-A1 | ANTITUMOR 2-AMINOCARBONYL-1,2-BIS(METHYLSULFONYL)-1-(SUBSTITUTED)HYDRAZINES | YALE UNIVERSITY (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5637619-A | Antitumor 2-aminocarbonyl-1, 2-bis(methylsulfonyl)-1-(substituted)hydrazines | YALE UNIVERSITY (US) | 1997-06-10 | — | — | US | disclosed |
| WO-1997002029-A1 | ANTITUMOR 2-AMINOCARBONYL-1,2-BIS(METHYLSULFONYL)-1-(SUBSTITUTED)HYDRAZINES | YALE UNIVERSITY (US) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | CA12 25/4885CA1 61/4885CA9 24/4885 |
| US-20260137698-A1 | CYCLIN-DEPENDENT KINASE 7 INHIBITORS | CDK7, CDK6, CDK3 | CA12 3596/4885CA1 2214/4885CA9 1360/4885 |
| US-20230137849-A1 | USE OF A COMPOUND OF THE DIURETICS CLASS FOR TREATING CANCER | ABCC4, ATP6V1B1, ABCC2 | CA12 239/4885CA1 743/4885CA9 137/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | CA12 4778/4885CA1 4827/4885CA9 4769/4885 |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | GLS, GLUL, GLS2 | CA12 2905/4885CA1 1694/4885CA9 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.